Drug Profile
GT 002
Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Lund University
- Developer Gabather
- Class Antipsychotics; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
- Preclinical Cognition disorders; Unspecified
Most Recent Events
- 11 Apr 2024 Gabather and Centre for Neuropsychiatric Schizophrenia Research agree to initiate clinical trial of GT 002 for Schizophrenia
- 11 Apr 2024 Interim adverse events data from a phase I EEG/fMRI target engagement trial released by Gabather
- 11 Apr 2024 Gabather in collaboration with Centre for Neuropsychiatric Schizophrenia Research plans a phase II trial for Schizophrenia in Denmark